Pioneering a New Frontier in Drug Discovery

Spun out of the MIT Media Lab, DeepCure has developed an AI/ML-based drug discovery platform that leverages MolDB, its proprietary database of over 1 trillion chemistries, to find novel small molecule drugs for previously undruggable targets. Instead of merely improving on physics-based modeling or optimizing binding associations, DeepCure leverages novel chemistry space to deliver high quality scaffolds for effective therapeutics.

A Comprehensive Platform to Expand the Universe of Druggable Enzymes

Traditional small-molecule drug development has focused on active and allosteric sites, but many targets prove to be intractable through this approach. Exo Therapeutics focuses on development of new therapeutics by identifying a novel class of targets called exosites. Exosites are distal and unique from the traditional sites, and exosite-targeted therapeutics may modulate binding affinity between an enzyme and a substrate without affecting other activities, while also diminishing competitive binding and off-target effects.